Skip to main content

Table 2 Recent (2010 to present) putative prognostic biomarkers of prostate cancer discovered using various mass spectrometry platforms

From: Novel approaches for the identification of biomarkers of aggressive prostate cancer

Proteomic method Protein biomarker(s) Sample source Additional info References
2D-PAGE + MALDI-TOF/TOF Panel of 17 candidates Tissue: Gleason score 5
(n = 4) compared with Gleason score 7 (n = 4)
  Alaiya et al. [104]
  Panel of 6 candidates Tissue: localized (n = 7) compared with lymph node metastases (n = 1)   Pang et al. [105]
  Lamin A Tissue: low (n = 23) compared with
high (n = 23) Gleason
ROC AUCa = 0.88 Skvortsov et al. [106]
  Transthyretin Serum: n = 4   Wang et al. [107]
  Clusterin Serum: n = 4   Wang et al. [107]
Shotgun proteomics Panel of 5 markers Tissue (n = unknown)   Drake et al. [108]
  Panel of 3 markers Pooled serum: metastases (n = 5) compared with progressing (n = 5)   Rehman et al. [109]
  Panel of 7 candidates Pooled serum: metastases (n = 5) compared with progressing (n = 5)   Rehman et al. [109]
  Panel of 5 markers Serum: Gleason <7 (n = 27) compared with ≤7 (n = 27) ROC AUCa = 0.79 Cima et al. [86]
  Acetyl-coenzyme A acetyltransferase Cell lines: androgen-dependent compared with androgen-independent   Saraon et al. [110]
Targeted proteomics Alpha-methylacyl-CoA racemase Pooled tissue: localized compared with metastases   Yocum et al. [111]
  Enhancer of zeste homolog 2 Pooled tissue: localized compared with metastases   Yocum et al. [111]
  1. aROC AUC, receiver operating characteristic area under the curve.